Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume – Here’s What Happened

Pharvaris N.V. (NASDAQ:PHVS) saw an uptick in trading volume on Wednesday . 487,339 shares traded hands during trading, an increase of 60% from the previous session’s volume of 303,990 shares.The stock last traded at $34.48 and had previously closed at $34.42.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PHVS. UBS Group set a $74.00 price objective on Pharvaris in a report on Wednesday, May 13th. Citigroup restated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Wells Fargo & Company began coverage on Pharvaris in a report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 price target for the company. Finally, Morgan Stanley raised their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.08.

Pharvaris Price Performance

The stock has a 50 day moving average price of $33.46 and a two-hundred day moving average price of $29.95. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -10.92 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.05). As a group, research analysts expect that Pharvaris N.V. will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Pharvaris

In other Pharvaris news, insider Anna Nijdam sold 2,670 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $30.87, for a total transaction of $82,422.90. Following the sale, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. This represents a 5.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the transaction, the director directly owned 315,167 shares of the company’s stock, valued at $11,185,276.83. This represents a 8.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 178,322 shares of company stock valued at $5,969,286.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PHVS. California State Teachers Retirement System increased its position in Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after buying an additional 520 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Pharvaris in the second quarter valued at approximately $41,000. GF Fund Management CO. LTD. purchased a new position in shares of Pharvaris during the fourth quarter worth approximately $35,000. Finally, Public Employees Retirement System of Ohio grew its position in shares of Pharvaris by 20.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after acquiring an additional 1,300 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.